Oncogenic activating point mutations in codon 12, 13, and 61 of the Kras gene are present in about 63% non-small cell lung cancers (Slebos et al., 1990), about 50% colorectal cancers (Porru et al., 2018) and 70–95% pancreatic cancers (Buscail et al., 2020). The gene discussed is KRAS; the disease is pancreatic neoplasm.